Tailoring treatments: pharmacogenomics in the management of neurodegenerative diseases.
Tailoring treatments: pharmacogenomics in the management of neurodegenerative diseases.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Ranchi, IN · Author affiliation
Department of Pharmaceutical Sciences, Jharkhand Rai University, Ranchi, 834010, Jharkhand, India.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Neurodegenerative diseases like Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis are growing more common worldwide, yet treatment is still poor. Conventional therapies can have unforeseen side effects, produce poor medication reactions, and take longer to work. This persistent treatment gap highlights the need for novel approaches to these disorders' complex distinctions. Pharmacogenomics, which examines how genetic differences affect drug response, is a promising new subject and an urgent solution. Pharmacogenomics tailors medicine selection and administration to each patient's genetic profile, addressing the main causes of poor treatment response and preventable side effects. This research has enabled precision medicine that can improve neurodegenerative disease therapy and reduce harm. In this in-depth research, we examine neurodegenerative disease management issues, pharmacogenomics breakthroughs, and how incorporating genetics to clinical practice can improve outcomes. We examine the latest evidence that genetics affect drug breakdown, efficacy, and toxicity. We also discuss the challenges and opportunities of applying this knowledge. Pharmacogenomic approaches must be widely applied to make medicines for these awful disorders safer, more effective, and really suited to patient needs, according to our compilation.